Skip to main content

Advertisement

SpringerLink
Log in

Heartburn refractory to proton-pump inhibitors

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

The most appropriate diagnostic and therapeutic approach to patients with heart-burn that persists despite the use of proton-pump inhibitor (PPI) therapy currently is not known. In general, patients with heartburn refractory to PPIs may have more than one explanation for their persistent symptoms. These include uncontrolled esophageal acid exposure (“PPI failure”) in a small subset of patients, as well as other potential etiologies in the majority of patients who have controlled esophageal acid exposure on PPI therapy (“PPI success”). Some potential explanations for persistent heartburn in this latter group include hypersensitivity to acid reflux, nonacidic or duodenogastric esophageal reflux, as well as functional heartburn. Patients who present with heartburn refractory to PPIs should be investigated further to determine the potential cause. We believe the diagnostic modality with the most clinical usefulness is 24-hour pH and multichannel intraluminal impedance monitoring with symptom index performed while the patient is on high-dose PPI therapy. This approach allows the patient to be properly categorized and also identifies a substantial proportion of patients who will have functional heartburn, a condition that should discourage the use of endoscopic or surgical therapies. Therapeutic options for patients with heartburn refractory to PPIs are limited and have not been thoroughly studied. As a result of the paucity of information, we favor a therapeutic approach based on the outcome of diagnostic testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Locke GR 3rd, Talley NJ, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997, 112:1448–1456.

    Article  PubMed  Google Scholar 

  2. Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005, 128:771–778.

    Article  PubMed  Google Scholar 

  3. Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther 2005, 22:79–94.

    Article  PubMed  CAS  Google Scholar 

  4. Castell DO, Kahrilas PJ, Richter JE, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575–583.

    Article  PubMed  CAS  Google Scholar 

  5. Dean BB, Gano AD, Knight K, et al.: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656–664.

    Article  PubMed  CAS  Google Scholar 

  6. The Gallup Organization: Gallup study of consumers’ use of stomach relief products. Princeton, NJ: The Gallup Organization; 2000.

    Google Scholar 

  7. Egan LJ, Myhre GM, Mays DC, et al.: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003, 17:1521–1528.

    Article  PubMed  CAS  Google Scholar 

  8. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998, 93:763–767.

    Article  PubMed  CAS  Google Scholar 

  9. Nzeako UC, Murray JA: An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002, 16:1309–1316.

    Article  PubMed  CAS  Google Scholar 

  10. Galmiche JP, Clouse RE, Balint A, et al.: Functional esophageal disorders. Gastroenterology 2006, 130:1459–1465.

    Article  PubMed  Google Scholar 

  11. Sgouros SN, Bergele C, Mantides A: Eosinophilic esophagitis in adults: a systematic review. Eur J Gastroenterol Hepatol 2006, 18:211–217.

    Article  PubMed  Google Scholar 

  12. Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996, 110:1982–1996.

    Article  PubMed  CAS  Google Scholar 

  13. Tack J, Koek G, Demedts I, et al.: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004, 99:981–988.

    Article  PubMed  CAS  Google Scholar 

  14. Bautista JM, Wong WM, Pulliam G, et al.: The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005, 50:1909–1915.

    Article  PubMed  Google Scholar 

  15. Charbel S, Khandwala F, Vaezi MF: The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005, 100:283–289.

    Article  PubMed  Google Scholar 

  16. Mainie I, Tutuian R, Shay S, et al.: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006, 55:1398–1402.

    Article  PubMed  CAS  Google Scholar 

  17. Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastrooesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14:1595–1603.

    Article  PubMed  CAS  Google Scholar 

  18. Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006, 4:50–56.

    Article  PubMed  CAS  Google Scholar 

  19. Fackler WK, Ours TM, Vaezi MF, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002, 122:625–632.

    Article  PubMed  CAS  Google Scholar 

  20. Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003, 98:545–550.

    Article  PubMed  Google Scholar 

  21. Lidums I, Lehmann A, Checklin H, et al.: Control of transient lower sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000, 118:7–13.

    Article  PubMed  CAS  Google Scholar 

  22. Zhang Q, Lehmann A, Rigda R, et al.: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19–24.

    Article  PubMed  CAS  Google Scholar 

  23. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastrooesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243–251.

    Article  PubMed  CAS  Google Scholar 

  24. Koek GH, Sifrim D, Lerut T, et al.: Effect of the GABA (B) agonist baclofen in patients with symptoms of duodenogastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397–1402.

    Article  PubMed  CAS  Google Scholar 

  25. Degen L, Petrig C, Studer D, et al.: Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005, 17:821–826.

    Article  PubMed  CAS  Google Scholar 

  26. Tutuian R, Mainie I, Allan R, et al.: Effects of a 5-HT (4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006, 24:155–162.

    Article  PubMed  CAS  Google Scholar 

  27. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14:1503–1509.

    Article  PubMed  CAS  Google Scholar 

  28. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al.: Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006, 4:442–450.

    Article  PubMed  CAS  Google Scholar 

  29. Prakash C, Clouse RE: Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44:2373–2379.

    Article  PubMed  CAS  Google Scholar 

  30. Varia I, Logue E, O’Connor C, et al.: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000, 140:367–372.

    Article  PubMed  CAS  Google Scholar 

  31. Gorelick AB, Koshy SS, Hooper FG, et al.: Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998, 275:G460–G466.

    PubMed  CAS  Google Scholar 

  32. Peghini PL, Katz PO, Castell DO: Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998, 42:807–813.

    Article  PubMed  CAS  Google Scholar 

  33. Broekaert D, Fischler B, Sifrim D, et al.: Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006, 23:365–370.

    Article  PubMed  CAS  Google Scholar 

  34. Arts J, Tack J, Galmiche JP: Endoscopic antireflux therapies. Gut 2004, 53:1207–1214.

    Article  PubMed  CAS  Google Scholar 

  35. Arts J, Lerut T, Rutgeerts P, et al.: A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci 2005, 50:351–356.

    Article  PubMed  CAS  Google Scholar 

  36. Campos GM, Peters JH, DeMeester TR, et al.: Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999, 3:292–300.

    Article  PubMed  CAS  Google Scholar 

  37. Swoger J, Ponsky J, Hicks DM, et al.: Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006, 4:433–441.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GI Neuromuscular Disorders Program, Section of Gastroenterology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    John D. Long

Authors
  1. Apurva Trivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Long.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trivedi, A., Long, J.D. Heartburn refractory to proton-pump inhibitors. Curr Treat Options Gastro 10, 47–56 (2007). https://doi.org/10.1007/s11938-007-0056-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-007-0056-5

Keywords

Search

Navigation